Duloxetine-induced liver injury in patients with major depressive disorder

Psychiatry Investigation

Volumn 8, Issue 3, 2011, Pages 269-271

  Kang, Seung Gul ^a   Park, Young Min ^b   Lee, Heon Jeong ^c   Yoon, Byungmun ^d  

^a Catholic University of Daegu   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d Department of Psychiatry   (South Korea)

Author keywords

Duloxetine; Liver injury; Major depressive disorder

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; AMYLASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DULOXETINE; ESCITALOPRAM; MIRTAZAPINE; PROTEIN; QUETIAPINE; VENLAFAXINE;

ADULT; AGED; ARTICLE; CASE REPORT; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; LABORATORY TEST; LIVER FUNCTION TEST; MAJOR DEPRESSION; MALE; SIDE EFFECT; SUICIDE ATTEMPT; TOXIC HEPATITIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 80053311384     PISSN: 17383684     EISSN: None     Source Type: Journal    
DOI: 10.4306/pi.2011.8.3.269     Document Type: Article

References (10)

1. Bleibel W, Kim S, D'Silva K, Lemmer ER. Drug-induced liver injury: review article. Dig Dis Sci 2007;52:2463-2471.
2. Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-954.
3. Temple RJ, Himmel MH. Safety of newly approved drugs: implications for prescribing. JAMA 2002;287:2273-2275.
4. Park YM, Lee BH, Lee HJ, Kang SG. Cholestatic jaundice induced by duloxetine in a patient with major depressive disorder. Psychiatry Investig 2010;7:228-230.
5. Wernicke J, Pangallo B, Wang F, Murray I, Henck JW, Knadler MP, et al. Hepatic effects of duloxetine-I: non-clinical and clinical trial data. Curr Drug Saf 2008;3:132-142.
6. Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight place-bo-controlled clinical trials. Hum Psychopharmacol 2005;20:327-341.
7. Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med 2006;7:373-385.
8. Hanje AJ, Pell LJ, Votolato NA, Frankel WL, Kirkpatrick RB. Case report: fulminant hepatic failure involving duloxetine hydrochloride. Clin Gastroenterol Hepatol 2006;4:912-917.
9. Holt MP, Ju C. Mechanisms of drug-induced liver injury. AAPS J 2006; 8:E48-E54.
10. McIntyre RS, Panjwani ZD, Nguyen HT, Woldeyohannes HO, Alsuwaidan M, Soczynska JK, et al. The hepatic safety profile of duloxetine: a review. Expert Opin Drug Metab Toxicol 2008;4:281-285.